SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Hawwa Alao, T. Jake Liang, Alternative interferons and immunomodulators in the treatment of hepatitis C, Liver International, 2014, 34,
  2. 2
    Tatyana O Kabilova, Larisa V Kovtonyuk, Evgeniy V Zonov, Elena I Ryabchikova, Nelly A Popova, Valeriy P Nikolin, Vasiliy I Kaledin, Marina A Zenkova, Valentin V Vlassov, Elena L Chernolovskaya, Immunotherapy of hepatocellular carcinoma with small double-stranded RNA, BMC Cancer, 2014, 14, 1, 338

    CrossRef

  3. 3
    Ludger Klimek, Martin F Bachmann, Gabriela Senti, Thomas M Kündig, Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs, Expert Review of Clinical Immunology, 2014, 10, 8, 1059

    CrossRef

  4. 4
    Shujuan Lv, Jun Wang, Shuang Dou, Xianzhu Yang, Xiang Ni, Rui Sun, Zhigang Tian, Haiming Wei, Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection, Hepatology, 2014, 59, 2
  5. 5
    K. Kobiyama, T. Aoshi, H. Narita, E. Kuroda, M. Hayashi, K. Tetsutani, S. Koyama, S. Mochizuki, K. Sakurai, Y. Katakai, Y. Yasutomi, S. Saijo, Y. Iwakura, S. Akira, C. Coban, K. J. Ishii, Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist, Proceedings of the National Academy of Sciences, 2014, 111, 8, 3086

    CrossRef

  6. 6
    Mira C Patel, Kari Ann Shirey, Lioubov M Pletneva, Marina S Boukhvalova, Alfredo Garzino-Demo, Stefanie N Vogel, Jorge CG Blanco, Novel drugs targeting Toll-like receptors for antiviral therapy, Future Virology, 2014, 9, 9, 811

    CrossRef

  7. 7
    Mei Qin, Yong Li, Xu Yang, HongQuan Wu, Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis, Immunopharmacology and Immunotoxicology, 2014, 36, 4, 251

    CrossRef

  8. 8
    Li Tang, Xiaoyan Feng, Feng He, Rui Huang, Jing He, Bingshui Xiu, Kun Chen, Xiqin Yang, Shigan Ling, Heqiu Zhang, Construction of an Immunostimulatory Plasmid, pUCpGs10, and Research on its Immune Adjuvant Effect, Molecular Biotechnology, 2013, 54, 1, 58

    CrossRef

  9. 9
    Gustaf Ahlén, Lars Frelin, Erwin Daniel Brenndörfer, Anette Brass, Ola Weiland, Margaret Chen, Matti Sällberg, Containing “The Great Houdini” of viruses: Combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C, Drug Resistance Updates, 2013, 16, 3-5, 60

    CrossRef

  10. You have free access to this content10
    K Gibbert, JF Schlaak, D Yang, U Dittmer, IFN-α subtypes: distinct biological activities in anti-viral therapy, British Journal of Pharmacology, 2013, 168, 5
  11. 11
    Zuzanna Makowska, Tanja Blumer, François H.T. Duong, Nicola La Monica, Ekambar R. Kandimalla, Markus H. Heim, Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist, Journal of Hepatology, 2013, 58, 4, 743

    CrossRef

  12. 12
    Jessica Howell, Peter Angus, Paul Gow, Kumar Visvanathan, Toll-like receptors in hepatitis C infection: Implications for pathogenesis and treatment, Journal of Gastroenterology and Hepatology, 2013, 28, 5
  13. 13
    Valérie Martel-Laferrière, Douglas Dieterich, Emerging Therapeutic Options for Hepatitis C, 2013,

    CrossRef

  14. 14
    Jan Petrasek, Timea Csak, Gyongyi Szabo, 2013,

    CrossRef

  15. 15
    Petros C. Benias, Kavitha Gopal, Henry Bodenheimer, Neil D. Theise, Hepatic expression of toll-like receptors 3, 4, and 9 in primary biliary cirrhosis and chronic hepatitis C, Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 5, 448

    CrossRef

  16. 16
    Megan Crane, Kumar Visvanathan, Sharon R. Lewin, HIV Infection and TLR Signalling in the Liver, Gastroenterology Research and Practice, 2012, 2012, 1

    CrossRef

  17. 17
    Giel R. Gaajetaan, Cathrien A. Bruggeman, Frank R Stassen, The type I interferon response during viral infections: a “SWOT” analysis, Reviews in Medical Virology, 2012, 22, 2
  18. 18
    Hannah M. Jones, Phylinda L. S. Chan, Piet H. van der Graaf, Robert Webster, Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C, British Journal of Clinical Pharmacology, 2012, 73, 1
  19. 19
    Natravis Cox, Hans Tillmann, Emerging pipeline drugs for hepatitis B infection, Expert Opinion on Emerging Drugs, 2011, 16, 4, 713

    CrossRef

  20. 20
    Mona Hedayat, Mihai G Netea, Nima Rezaei, Targeting of Toll-like receptors: a decade of progress in combating infectious diseases, The Lancet Infectious Diseases, 2011, 11, 9, 702

    CrossRef

  21. 21
    Abbi L Engel, Gregory E Holt, Hailing Lu, The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system, Expert Review of Clinical Pharmacology, 2011, 4, 2, 275

    CrossRef

  22. 22
    Norbert Donhauser, Martin Helm, Kathrin Pritschet, Philipp Schuster, Moritz Ries, Klaus Korn, Jörg Vollmer, Barbara Schmidt, Differential Effects of P-Class Versus Other CpG Oligodeoxynucleotide Classes on the Impaired Innate Immunity of Plasmacytoid Dendritic Cells in HIV Type 1 Infection, AIDS Research and Human Retroviruses, 2010, 26, 2, 161

    CrossRef

  23. 23
    Ivan Hirsch, Christophe Caux, Uzma Hasan, Nathalie Bendriss-Vermare, Daniel Olive, Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer, Trends in Immunology, 2010, 31, 10, 391

    CrossRef

  24. 24
    Veronica D. Gonzalez, Alan L. Landay, Johan K. Sandberg, Innate immunity and chronic immune activation in HCV/HIV-1 co-infection, Clinical Immunology, 2010, 135, 1, 12

    CrossRef

  25. 25
    Francesco Iannuzzella, Augusto Vaglio, Giovanni Garini, Management of Hepatitis C Virus-related Mixed Cryoglobulinemia, The American Journal of Medicine, 2010, 123, 5, 400

    CrossRef

  26. 26
    Vincent Mallet, Anaïs Vallet-Pichard, Stanislas Pol, New trends in hepatitis C management, La Presse Médicale, 2010, 39, 4, 446

    CrossRef

  27. 27
    Mary Struthers, Andrew J. Bett, Thomas Wisniewski, Sheri A. Dubey, Melissa Precopio, Weiwen Jiang, Zhenhua Sun, Hao Wang, Ireneusz Nowak, Mallikarjuna R. Putta, Dong Yu, Jimmy X. Tang, Ekambar R. Kandimalla, Sudhir Agrawal, Danilo R. Casimiro, Synthesis and immunological activities of novel agonists of toll-like receptor 9, Cellular Immunology, 2010, 263, 1, 105

    CrossRef

  28. 28
    Iwona Mozer-Lisewska, Jan Sikora, Arleta Kowala-Piaskowska, Mariusz Kaczmarek, Grzegorz Dworacki, Jan Żeromski, The Incidence and Significance of Pattern-Recognition Receptors in Chronic Viral Hepatitis Types B and C in Man, Archivum Immunologiae et Therapiae Experimentalis, 2010, 58, 4, 295

    CrossRef

  29. 29
    Mohamed L. Salem, Maha EL-Demellawy, Abdel Raouf Abou El-Azm, The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus, Cellular Immunology, 2010, 262, 2, 96

    CrossRef

  30. 30
    Jan Petrasek, Pranoti Mandrekar, Gyongyi Szabo, Toll-Like Receptors in the Pathogenesis of Alcoholic Liver Disease, Gastroenterology Research and Practice, 2010, 2010, 1

    CrossRef

  31. 31
    Jun Wu, Zhongji Meng, Min Jiang, Ejuan Zhang, Martin Trippler, Ruth Broering, Agnes Bucchi, Frank Krux, Ulf Dittmer, Dongliang Yang, Michael Roggendorf, Guido Gerken, Mengji Lu, Joerg F. Schlaak, Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific, Immunology, 2010, 129, 3
  32. 32
    Ulrike Mihm, Oliver Ackermann, Christoph Welsch, Eva Herrmann, Wolf Peter Hofmann, Natalia Grigorian, Martin Walter Welker, Thomas Lengauer, Stefan Zeuzem, Christoph Sarrazin, Clinical relevance of the 2′–5′-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C, Journal of Hepatology, 2009, 50, 1, 49

    CrossRef

  33. 33
    Kei Amemiya, Jennifer L. Meyers, Taralyn E. Rogers, Randy L. Fast, Anthony D. Bassett, Patricia L. Worsham, Bradford S. Powell, Sarah L. Norris, Arthur M. Krieg, Jeffrey J. Adamovicz, CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague, Vaccine, 2009, 27, 16, 2220

    CrossRef

  34. 34
    Daniel P Webster, Paul Klenerman, Jane Collier, Katie JM Jeffery, Development of novel treatments for hepatitis C, The Lancet Infectious Diseases, 2009, 9, 2, 108

    CrossRef

  35. 35
    Kimberly A. Forde, K. Rajender Reddy, Hepatitis C Virus Infection and Immunomodulatory Therapies, Clinics in Liver Disease, 2009, 13, 3, 391

    CrossRef

  36. 36
    Katrin Reppe, Thomas Tschernig, Anke Lührmann, Vincent van Laak, Karsten Grote, Maren V. Zemlin, Birgitt Gutbier, Holger C. Müller, Mischo Kursar, Hartwig Schütte, Simone Rosseau, Reinhard Pabst, Norbert Suttorp, Martin Witzenrath, Immunostimulation with Macrophage-Activating Lipopeptide-2 Increased Survival in Murine Pneumonia, American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 4, 474

    CrossRef

  37. 37
    Jörg Vollmer, Arthur M. Krieg, Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists, Advanced Drug Delivery Reviews, 2009, 61, 3, 195

    CrossRef

  38. You have free access to this content38
    J. De Bruijne, C. J. Weegink, P. L. M. Jansen, H. W. Reesink, New developments in the antiviral treatment of hepatitis C, Vox Sanguinis, 2009, 97, 1
  39. 39
    Virginia Clark, David R. Nelson, Novel Interferons for Treatment of Hepatitis C Virus, Clinics in Liver Disease, 2009, 13, 3, 351

    CrossRef

  40. 40
    Jeremy L. Herrmann, Rescuing Macrophage Function Following Severe Thermal Injury, Journal of Surgical Research, 2009, 157, 2, 158

    CrossRef

  41. 41
    C. Guiducci, R. L. Coffman, F. J. Barrat, Signalling pathways leading to IFN-α production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications, Journal of Internal Medicine, 2009, 265, 1
  42. 42
    Chi-Mu Chuang, Archana Monie, Annie Wu, Chih-Ping Mao, Chien-Fu Hung, Treatment with LL-37 Peptide Enhances Antitumor Effects Induced by CpG Oligodeoxynucleotides Against Ovarian Cancer, Human Gene Therapy, 2009, 20, 4, 303

    CrossRef

  43. 43
    Kaveri Gupta, Curtis Cooper, A Review of the Role of CpG Oligodeoxynucleotides as Toll-Like Receptor 9 Agonists in Prophylactic and Therapeutic Vaccine Development in Infectious Diseases, Drugs in R & D, 2008, 9, 3, 137

    CrossRef

  44. 44
    Thomas Meyer, Eggert Stockfleth, Clinical investigations of Toll-like receptor agonists, Expert Opinion on Investigational Drugs, 2008, 17, 7, 1051

    CrossRef

  45. 45
    Poonam Mishra, Donald M. Jensen, Hepatitis C: current and future therapies, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2008, 75, 4
  46. 46
    Krystle Lang, David B Weiner, Immunotherapy for HCV infection: next steps, Expert Review of Vaccines, 2008, 7, 7, 915

    CrossRef

  47. 47
    Philippe Halfon, Marc Bourlière, Hacène Khiri, Guillaume Pénaranda, Agnes Martineau, Valérie Oulès, Jérôme Courcambeck, Patrick Philibert, Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy, AIDS, 2008, 22, 13, 1694

    CrossRef

  48. 48
    Magali Terme, Evelyn Ullrich, Nicolas F Delahaye, Nathalie Chaput, Laurence Zitvogel, Natural killer cell–directed therapies: moving from unexpected results to successful strategies, Nature Immunology, 2008, 9, 5, 486

    CrossRef

  49. 49
    Michael von Wagner, Wolf Peter Hofmann, Gerlinde Teuber, Thomas Berg, Tobias Goeser, Ulrich Spengler, Holger Hinrichsen, Hans Weidenbach, Guido Gerken, Michael Manns, Peter Buggisch, Eva Herrmann, Stefan Zeuzem, Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection, Hepatology, 2008, 48, 5
  50. 50
    Matthew L. Albert, Jérémie Decalf, Stanislas Pol, Plasmacytoid dendritic cells move down on the list of suspects: In search of the immune pathogenesis of chronic hepatitis C, Journal of Hepatology, 2008, 49, 6, 1069

    CrossRef

  51. 51
    Ekihiro Seki, David A. Brenner, Toll-like receptors and adaptor molecules in liver disease: Update, Hepatology, 2008, 48, 1
  52. 52
    Julie Sheldon, Pablo Barreiro, Vincent Vincent, Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection, Expert Opinion on Investigational Drugs, 2007, 16, 8, 1171

    CrossRef

  53. 53
    Michael P. Manns, Graham R. Foster, Jürgen K. Rockstroh, Stefan Zeuzem, Fabien Zoulim, Michael Houghton, The way forward in HCV treatment — finding the right path, Nature Reviews Drug Discovery, 2007, 6, 12, 991

    CrossRef

  54. 54
    Britta Hoehn, John J. Rossi, Nucleic Acid-Based Therapies,